Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
about
Humanized mice: novel model for studying mechanisms of human immune-based therapiesT cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccinationHeat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artSuppression of T-cell expansion by melanoma is exerted on resting cells.Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosaHuman renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations.Immunological mechanisms of the antitumor effects of supplemental oxygenation.The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapiesEfficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independentThe polarization of immune cells in the tumour environment by TGFbeta.Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced 'brakes' on host immunity.Grp94 in complexes with IgG is a soluble diagnostic marker of gastrointestinal tumors and displays immune-stimulating activity on peripheral blood immune cells.Active immunotherapy for non-small-cell lung cancer: moving toward a reality.Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potentialImmunotherapy as a strategy for the treatment of non-small-cell lung cancer.Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
P2860
Q26996648-6291DD51-CE10-4467-9D5A-7D3207309199Q28274469-86444993-F46D-4A88-8092-42AE3BD601B9Q33585305-C7305EA8-E936-43C0-9138-B5C0678E9B04Q33724352-24A6CA90-789A-4ECE-8F43-31CAF99BBA1BQ33907628-E5B258A7-D604-4C8D-958C-2B94F49450C2Q34206191-4B31EFD6-7596-4216-A069-193B280680B0Q34727695-9975C811-E08A-46A5-91A8-95203334D120Q35070193-90EBE5E2-5084-45D8-91E7-F3977A40E78AQ36269330-A1914FF2-C14B-4DA9-B87C-C2422AC6343FQ37285838-C9F6B0F9-1C2E-4584-8100-2106A2DD168EQ37359887-6160E174-82B8-468E-942C-5865BFD4C270Q37454364-31167BBC-1777-4331-81F1-2DAD64B8504DQ37487763-2C227ABF-E38E-4E20-8315-64E122490B5FQ37687316-F978FB8C-D9D6-4CDF-A4B1-5F5E31E19EE3Q37945644-29A3AB63-4138-4578-86AE-CA914DD93FFCQ38164258-2891CE19-4DBC-4FA4-ACEA-44192F941781Q38198491-256335CA-D704-4E93-A75A-DA63818EE152Q41878129-CB1D4EC5-EF79-4D2F-BA87-5DDFB1A67ADCQ44703429-4D801604-F173-417F-840D-9F755E762AE2Q51495627-3C32CCB2-5B4A-4792-87DF-1A99708FC8DB
P2860
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
@en
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
@nl
type
label
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
@en
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
@nl
prefLabel
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
@en
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
@nl
P2093
P2860
P1433
P1476
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination.
@en
P2093
Eckhard R Podack
Joseph D Rosenblatt
Taylor H Schreiber
Vadim V Deyev
P2860
P304
P356
10.1158/0008-5472.CAN-08-3706
P407
P577
2009-02-17T00:00:00Z